disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Administrative Policy Statements prepared by CSMG Co. and its affiliates (including CareSource) do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Administrative Policy Statement. If there is a conflict between the Administrative Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination. 1



dose administered at least 2 months after either completion of primary vaccination with any authorized or approved monovalent COVID-19 vaccine, or receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. For the Pfizer-BioNTech Bivalent formulation, a 0.2 mL dose (10 *μ*

COVID-19 Vaccination

Janssen COVID-19 vaccine as the first single-shot COVID-19 vaccine in individuals 18 years of age or older for the prevention of COVID-19. The use of the Janssen COVID-19 vaccine under the EUA should be implemented in conjunction with ACIP's interim recommendations for allocating initial supplies of COVID-19 vaccines. The interim

-



C. Definitions

Emergency Use Authorization (EUA) – A mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies.
Vaccine Adverse Event Reporting System (VAERS) – A national early warning system to detect possible safety problems in vaccines used in the United States.
Immunization Information System (IIS) – A confidential, population-based, computerized databases that record all immunization doses administered by participating providers to persons residing within a specific geopolitical area.

D. Policy

I. COVID-19 vaccination providers participating in the Centers for Disease Control and Prevention (CDC) COVID -19 Vaccination Program are required to sign a CDC COVID-19 Vaccination Program Provider Agreement. Providers are responsible for adhering to all requirements outlined in the agreement.
II. Providers must follow the prioritization schedule as determined by the state's and/or the Department of Health's plan for distributing the vaccines (e.g., Phase 1a includes healthcare personnel, Phase 1b includes persons ≥ 75 years of age, etc.):
    A. COVID-19 vaccine providers are prohibited from selling USG-purchased COVID-19 vaccine, receiving any inducement (whether direct or indirect) for vaccinating (or providing COVID-19 vaccine to be used for vaccinating) and individual who is not currently eligible to receive COVID-19 vaccine as a member of a group currently authorized under prioritization specified by CDC/ACIP, the state/territory's governor or other relevant public health authority, or otherwise diverting COVID-19 vaccine from the CDC COVID-19 Vaccination Program.
III. The member's age must be within the age group that is authorized to receive the COVID-19 vaccination:
    A. Pfizer-BioNTech: age 6 months or greater;
    B. Moderna: age 6 months or greater;
    C. Janssen: age 18 years or greater;
    D. Novavax: age 12 years or greater.
IV. The vaccination provider must follow the vaccine schedule as outlined in the EUA fact sheet.
    A. Pfizer-BioNTech: 2 doses, 21 days apart; third dose 28 days apart for those who have undergone solid organ transplantation or have a diagnosis with an equivalent level of immunocompromise;
    B. Moderna: 2 doses, 28 days apart; third dose 28 days apart for those who have undergone solid organ transplantation or have a diagnosis with an equivalent level of immunocompromise;
    C. Janssen: 1 dose for primary vaccination;
    D. Novavax: 2 doses, 21 days apart;
    E. People ages 6 months through 64 years, and especially males ages 12 through 39 years, may consider getting the 2nd primary Pfizer-BioNTech, Moderna, or Novavax 8 weeks after the 1st dose.
V. The provider must communicate to the individual receiving the vaccine or their caregiver, information consistent with the "Fact Sheet for Recipients and Caregivers" prior to receiving the vaccine.

COVID-19 Vaccination
INDIANA

09/01/2021	Policy revised to update age for Pfizer vaccine, and update vaccine schedule for Pfizer and Moderna vaccine.
11/30/2021	Policy revised to update age for Pfizer vaccine, Pfizer
12/09/2021	
3/4/2022	
10/20/2022